Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Amphenol | Applied Digital | Pfizer | |
|---|---|---|---|
| Moat rating | narrow The FY2025 10-K describes a real, well-defended position but declines every claim that would make it structural. The strength is in how Amphenol gets designed in: it 'works closely with its customers at the design stage to create and manufacture innovative solutions', and the R&D discussion says this 'often results in the Company obtaining approved vendor status for its customers' new products and programs'. The demand side reinforces it — 'for many years, customers have generally been consolidating their lists of qualified suppliers to companies that have the ability to meet certain technical, quality, delivery and other standards while maintaining geographic flexibility and competitive prices'. Against that, the Competition section opens with 'the Company encounters competition in all areas of its business', lists price among the five bases on which it competes ('technology innovation, product quality and performance, price, customer service and delivery time'), and names thirteen primary competitors: Aptiv, Belden, Corning, Foxconn Interconnect Technology, Glenair, HUBER+SUHNER, ICT Luxshare, Jonhon, Molex, Rosenberger, Sensata, TE Connectivity and Yazaki, 'among others', plus 'a large number of smaller companies who compete in specific geographies, markets or products'. The IP section explicitly declines the patent story: 'we do not believe that our competitive position or our operations are dependent upon or would be materially impacted by the loss of any single patent or group of related patents'. Scale is real but not commanding — the filing estimates the worldwide interconnect, cable-assembly, antenna, cable and sensor market at 'approximately $500 billion in 2025' against its own $23,094.7 million of net sales, and calls the industry 'highly fragmented'. A moat that has to be re-won socket by socket in a fragmented market against named peers of comparable standing is narrow, not wide. | none The FY2026 10-K (filed 2026-07-29) shows contracted revenue, not a demonstrated competitive edge. About 1,410 MW is leased under 15-year take-or-pay, non-cancellable base terms worth about $36.2 billion, but only about 100 MW of the roughly 1.5 GW that is contracted and either operating or under construction was operating and earning revenue at May 31, 2026, and Item 1A says "lessees may have the right to terminate applicable leases if there are significant delays in construction." Item 1A also concedes "We do not have the resources to compete with larger providers of similar products or services at this time," and the Competition section names 13 power-advantaged developers the company competes with. Signed leases give revenue visibility, but the filing does not show a durable advantage. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | switching costs The filing locates the advantage in the design-in relationship, not in patents or in raw scale. Its stated strategy is to 'expand the scope and number of its preferred supplier relationships with customers across its diverse end markets', achieved by working 'closely with its customers at the design stage'; the payoff named in the R&D section is 'approved vendor status for its customers' new products and programs'. The Customers section describes the resulting stickiness in structural terms — supplier lists are being consolidated to those who clear technical, quality and delivery standards, and 'our relationships with them typically date back many years' — and it says these close relationships 'allow the Company to better anticipate and respond to these customer needs when designing new products'. Amphenol itself disclaims IP dependence and instead 'rel[ies] upon trade secrets, manufacturing know-how, continuing technological innovations and licensing opportunities'. Cost_scale is a genuine reinforcement rather than the primary source: the Company manufactures 'at facilities in approximately 40 countries', states that 'global presence is an important competitive advantage', and 'has established low-cost manufacturing and assembly facilities around the world' — but that footprint serves the design-in relationship (proximity, real-time capability, supply-base consolidation for the customer) rather than standing alone. | none The 10-K claims three advantages: power-advantaged sites (it believes securing power and interconnection ahead of demand is 'the principal constraint on new HPC capacity and a core differentiator for us from many of our competitors'), a standardized 'franchise-style' design, and hyperscaler master service and master telecom service agreements 'that are difficult to obtain.' The filing does not show any of them to be durable. Its Competition section says competition 'centers on securing and developing sites with access to large-scale, reliable, and cost-competitive power and interconnection' and names 13 power-advantaged developers going after the same leases, and Item 1A concedes it lacks the resources to compete with larger providers. Signed leases are take-or-pay and non-cancellable, so a tenant leaving for convenience owes 'the full remaining contractual value,' but that is contractual lock-in on each lease rather than a moat source, so no moat type is assigned. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | co leader The filing claims leadership repeatedly but always in a served market, never across the industry, and always alongside named peers. In IT datacom it is unambiguous — 'Amphenol is a market leader in interconnect development for the information technology and data communications ("IT datacom") market', with 'industry-leading high-speed, power and active and passive fiber optic interconnect technologies, together with superior simulation and testing capability and cost effectiveness'. In defence it is stronger still: 'Amphenol is a world leader in the design, manufacture and supply of high-performance interconnect systems for harsh environment aerospace and defense applications', offering 'an unparalleled product breadth' and 'participating in major programs from the earliest inception across each phase of the production cycle'. Elsewhere the language is the indefinite article — 'a leading supplier' in automotive, 'a leading provider' in commercial aerospace, 'a leading global provider' in communications networks, 'a technology leader' in industrial. At the company level it says only 'one of the world's largest', and its Competition section places Molex and TE Connectivity, among others, on the same field. Roughly $23.1 billion of net sales against an estimated $500 billion market that the filing calls 'highly fragmented' is not a commanding share. | behind The 10-K makes no leadership claim and gives no ranking or share figure. Item 1A concedes "We do not have the resources to compete with larger providers of similar products or services at this time" and that some rivals have "substantially greater liquidity and financial resources than we do." Its Competition section places APLD against established operators (Digital Realty, Equinix), hyperscalers that build their own capacity, independent developers and 13 named power-advantaged developers (IREN, Cipher Digital, TeraWulf, Hut 8, Riot, CleanSpark, HIVE, Core Scientific, Bitdeer, Galaxy Digital, Fermi, Keel Infrastructure, MARA). | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | moderate Margin evidence is strong but the filing does not attribute it to price. Operating income rose to 25.4% of net sales in 2025 from 20.7% in 2024 and 20.4% in 2023 (adjusted operating margin 26.2% versus 21.7%), and the stated cause is volume and cost discipline: 'strong performance and disciplined cost control, which generated strong operating leverage on the significant growth experienced during the period'. Segment margins moved the same way for the same reason — Communications Solutions to 31.1% from 24.8%, Harsh Environment Solutions to 26.2% from 24.7%, Interconnect and Sensor Systems to 19.5% from 18.4% — each explained by 'strong operating performance on the higher sales volumes'. On the other side, price is one of the five bases the Company says it competes on, customers are consolidating supplier lists partly on 'competitive prices', and the input side is not fully controlled: difficulties obtaining raw materials 'may also negatively impact the pricing of materials and components sourced or used by the Company', with 'inflationary pressures and increased commodity prices' cited as a live cost risk. The ability to hold and expand margin through a demand surge is real; the ability to set price is not asserted anywhere in the document. | weak Item 1A says "Due to the limited number of hyperscalers, we expect that a limited number of customers will continue to account for a high percentage of our revenue for the foreseeable future," and that if customers' equipment usage declines or they discontinue use of its facilities, APLD "may be compelled to lower our lease prices in some instances or risk losing a significant customer." One customer was 59% of FY2026 revenue from continuing operations. Take-or-pay, non-cancellable terms protect contracted revenue over the base term, and Note 19 reports a $39.1M HPC Hosting segment profit on $385.3M of segment revenue in FY2026, but those terms are agreed with a small group of concentrated buyers. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | Amphenol is, in its own words, 'one of the world's largest designers, manufacturers and marketers of electrical, electronic and fiber optic connectors and interconnect systems, antennas, sensors and sensor-based products and coaxial, high-speed, fiber optic and specialty cable', selling into a market it sizes at roughly $500 billion in 2025 through three segments — Communications Solutions (52% of 2025 net sales), Harsh Environment Solutions (26%) and Interconnect and Sensor Systems (22%). The durable part of the business is the design-stage relationship that converts into approved-vendor status on customer programs, held together by manufacturing in approximately 40 countries, roughly 6,400 research, development and engineering employees at the end of 2025, and a deliberately flat structure of 'more than 140 general managers running unique, independent businesses'; diversification is real, with no single customer at 10% or more of net sales in 2025, 2024 or 2023 and about 65% of sales outside the United States. The FY2025 result shows what that position converts into under demand: net sales of $23,094.7 million, up 52% in U.S. dollars and 38% organically, with operating income at 25.4% of net sales against 20.7% in 2024 and 20.4% in 2023 — an expansion the filing attributes to 'strong performance and disciplined cost control, which generated strong operating leverage on the significant growth experienced during the period', not to price. The same filing bounds the story: it competes on price among other factors, names thirteen primary competitors, and is buying growth heavily — approximately $3.8 billion across five acquisitions in 2025, the Andrew (Outdoor Wireless Networks and Distributed Antenna Systems) business closed 31 January 2025, and CommScope's Connectivity and Cable Solutions business closed 9 January 2026 for approximately $10.5 billion, 'the largest acquisition in the Company's history' — with acquired businesses 'currently operating below the average operating margin of the Company'. | Applied Digital designs, builds and operates purpose-built, liquid-cooled HPC data centers, which it calls 'AI factories', and leases the capacity to CoreWeave and investment-grade hyperscalers. At May 31, 2026 its 10-K lists five campuses (Polaris Forge 1-3 and Delta Forge 1-2) with about 1,410 MW contracted under roughly 15-year take-or-pay, non-cancellable leases worth about $36.2 billion over the base terms. The filing claims three sources of advantage: it controls power-advantaged sites, it uses a standardized 'franchise-style' design built to deliver about 150 MW in about 14 to 18 months, and it holds hyperscaler master agreements that are 'difficult to obtain.' The same document shows how early the company is. About 100 MW was operating and earning revenue. One customer was 59% of FY2026 revenue from continuing operations. It competes with Digital Realty, Equinix, hyperscalers that build their own capacity and 13 named power-advantaged developers, and it concedes that it lacks the resources to compete with larger providers. Signed leases give long-dated revenue visibility, but the filing does not show a durable competitive advantage. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Amphenol occupies the physical interconnect layer of the AI build-out, and the filing makes that claim itself rather than leaving it inferred: it is 'a global provider of interconnect solutions to designers, manufacturers and operators of internet and artificial intelligence ("AI")-enabling systems', with products that 'enable a broad array of IT datacom systems and applications, including a growing range of systems to power AI and machine learning'. The exposure is material, not incidental. IT datacom was approximately 36% of 2025 net sales and grew by approximately $4,593.7 million on 'the continued acceleration in and strong demand for products used in next-generation AI-related applications', and backlog rose to approximately $8.9 billion at 31 December 2025 from approximately $6.1 billion a year earlier, an increase the filing says was 'primarily related to strong demand for the Company's products that support AI applications'. The AI pull also drove the segment mix — Communications Solutions net sales grew 71% organically 'with particular strength in AI-related applications'. It is nonetheless a diversified supplier, not an AI pure play: automotive (15%), industrial (19%), communications networks (10%), defense (9%), mobile devices (6%) and commercial aerospace (5%) make up the balance. | Developer and landlord of power-advantaged, liquid-cooled AI data-center capacity, leased long-term to CoreWeave and investment-grade hyperscalers. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.20 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |